Your Guide to Understanding Genetic Conditions

GNA11 gene

G protein subunit alpha 11

Normal Function

The *GNA11* gene provides instructions for making one component, the alpha (α) subunit, of a protein complex called a guanine nucleotide-binding protein (G protein). Each G protein is composed of three proteins called the alpha, beta, and gamma subunits. Specifically, the protein produced from the *GNA11* gene, called $G\alpha_{11}$, is the alpha subunit for a G protein called $G\alpha_{11}$.

In a process called signal transduction, G proteins trigger a complex network of signaling pathways that ultimately influence many cell functions. The G_{11} protein plays many roles in cells. It works with another protein called the calcium-sensing receptor (CaSR) to affect processes that regulate calcium levels in the blood. CaSR proteins in kidney cells and cells of the parathyroid gland sense when a certain concentration of calcium in the blood is reached; the CaSR protein then stimulates the G_{11} subunits,

including $G\alpha_{11}$, to send signals that block processes that increase the amount of calcium in the blood. In particular, this signaling blocks the production and release of a hormone called parathyroid hormone. Parathyroid hormone enhances the release of calcium into the blood, so blocking this hormone prevents calcium release. In the kidneys, which filter fluid and waste products in the body and can reabsorb needed nutrients and release them back into the blood, G_{11} signaling blocks the reabsorption of calcium from the filtered fluids.

 G_{11} signaling is also involved in the growth and division (proliferation) and self-destruction (apoptosis) of cells in tissues throughout the body, including those in the eyes, skin, heart, and brain.

Health Conditions Related to Genetic Changes

autosomal dominant hypocalcemia

At least five mutations in the *GNA11* gene have been found in individuals with autosomal dominant hypocalcemia type 2. This condition is characterized by low levels of calcium in the blood (hypocalcemia). The mutations involved in this condition change single protein building blocks (amino acids) in $G\alpha_{11}$. These genetic changes are called activating mutations because the altered alpha subunit is overactive, sending signals to block a rise in calcium levels, even when levels are very low. As a result, calcium levels in the blood remain abnormally low, causing hypocalcemia.

Hypocalcemia can cause muscle cramping and seizures, although about half of people with the condition have no associated health problems.

Because overactive $G\alpha_{11}$ signaling blocks the production of parathyroid hormone, the levels of this hormone in the blood can be abnormally low, which is known as hypoparathyroidism. For this reason, autosomal dominant hypocalcemia is sometimes referred to as autosomal dominant hypoparathyroidism.

cancers

The gene mutations that cause autosomal dominant hypocalcemia (described above) are typically inherited and found in every cell in the body (known as germline mutations). However, some gene mutations are not inherited and are instead acquired during a person's lifetime. These changes, which are called somatic mutations, are present only in certain cells. Somatic mutations in the *GNA11* gene have been found in cancerous tumors in the eye known as uveal melanomas. These tumors occur in the colored part of the eye (the iris) or in related tissues known as the ciliary body and the choroid (collectively, these tissues are called the uvea). Less commonly, *GNA11* gene mutations are associated with a type of skin tumor called a blue nevus, so named because of its characteristic bluish appearance. This type of growth is typically noncancerous. *GNA11* gene mutations are activating, leading to production of an overactive $G\alpha_{11}$ protein that stimulates uncontrolled proliferation of the pigment-producing cells (melanocytes) in the uvea or in the skin.

Individuals with uveal melanomas or blue nevi appear to have normal levels of calcium in their blood, and people with an inherited *GNA11*-related calcium concentration disorder do not seem to have an increased risk of developing one of these types of tumors.


other disorders

Germline mutations in the *GNA11* gene are also involved in a different condition related to abnormal calcium concentrations. Genetic changes that impair $G\alpha_{11}$ signaling cause familial hypocalciuric hypercalcemia type 2. In contrast to autosomal dominant hypocalcemia (described above), this condition is characterized by high levels of calcium in the blood (hypercalcemia) and low levels of calcium in the urine (hypocalciuria). Because $G\alpha_{11}$ signaling to block parathyroid hormone release is impaired, calcium levels in the blood rise, leading to hypercalcemia. Affected individuals typically have no symptoms related to the condition.

Chromosomal Location

Cytogenetic Location: 19p13.3, which is the short (p) arm of chromosome 19 at position 13.3

Molecular Location: base pairs 3,094,410 to 3,124,002 on chromosome 19 (Homo sapiens Annotation Release 108, GRCh38.p7) (NCBI)



Credit: Genome Decoration Page/NCBI

Other Names for This Gene

- FBH
- FBH2
- FHH2
- quanine nucleotide binding protein (G protein), alpha 11 (Gg class)

Additional Information & Resources

Educational Resources

- Biochemistry (fifth edition, 2002): G Proteins Cycle Between GDP- and GTP-Bound Forms
 - https://www.ncbi.nlm.nih.gov/books/NBK22592/#_A2060_
- Molecular Biology of the Cell (fourth edition, 2002): Trimeric G Proteins
 Disassemble to Relay Signals from G-Protein-linked Receptors
 https://www.ncbi.nlm.nih.gov/books/NBK26912/#_A2796_

Scientific Articles on PubMed

PubMed

https://www.ncbi.nlm.nih.gov/pubmed?term=%28GNA11%5BTIAB%5D%29+AND+%28%28Genes%5BMH%5D%29+OR+%28Genetic+Phenomena%5BMH%5D%29%29+AND+english%5Bla%5D+AND+human%5Bmh%5D+AND+%22last+1080+days%22%5Bdp%5D

OMIM

 GUANINE NUCLEOTIDE-BINDING PROTEIN, ALPHA-11 http://omim.org/entry/139313

Research Resources

- Atlas of Genetics and Cytogenetics in Oncology and Haematology http://atlasgeneticsoncology.org/Genes/GNA11ID43272ch19p13.html
- HGNC Gene Symbol Report http://www.genenames.org/cgi-bin/gene_symbol_report?q=data/ hgnc_data.php&hgnc_id=4379
- NCBI Gene https://www.ncbi.nlm.nih.gov/gene/2767
- UniProt http://www.uniprot.org/uniprot/P29992

Sources for This Summary

- OMIM: GUANINE NUCLEOTIDE-BINDING PROTEIN, ALPHA-11 http://omim.org/entry/139313
- Li D, Opas EE, Tuluc F, Metzger DL, Hou C, Hakonarson H, Levine MA. Autosomal dominant hypoparathyroidism caused by germline mutation in GNA11: phenotypic and molecular characterization. J Clin Endocrinol Metab. 2014 Sep;99(9):E1774-83. doi: 10.1210/jc.2014-1029. Epub 2014 May 13.
 Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/24823460
 Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4154081/
- Nesbit MA, Hannan FM, Howles SA, Babinsky VN, Head RA, Cranston T, Rust N, Hobbs MR, Heath H 3rd, Thakker RV. Mutations affecting G-protein subunit α11 in hypercalcemia and hypocalcemia. N Engl J Med. 2013 Jun 27;368(26):2476-86. doi: 10.1056/NEJMoa1300253. Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/23802516 Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3773604/
- Shoushtari AN, Carvajal RD. GNAQ and GNA11 mutations in uveal melanoma. Melanoma Res. 2014 Dec;24(6):525-34. doi: 10.1097/CMR.00000000000121. Review.
 Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/25304237
- Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, Obenauf AC, Wackernagel W, Green G, Bouvier N, Sozen MM, Baimukanova G, Roy R, Heguy A, Dolgalev I, Khanin R, Busam K, Speicher MR, O'Brien J, Bastian BC. Mutations in GNA11 in uveal melanoma. N Engl J Med. 2010 Dec 2;363(23):2191-9. doi: 10.1056/NEJMoa1000584. Epub 2010 Nov 17. Citation on PubMed: https://www.ncbi.nlm.nih.gov/pubmed/21083380
 Free article on PubMed Central: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3107972/

Reprinted from Genetics Home Reference:

https://ghr.nlm.nih.gov/gene/GNA11

Reviewed: February 2015 Published: March 21, 2017

Lister Hill National Center for Biomedical Communications U.S. National Library of Medicine National Institutes of Health Department of Health & Human Services